M. Humbert (Le Kremlin-Bicêtre, France), A. Ghofrani (Giessen, Germany)
Randomized, controlled, prospective multicenter study: Training improves peak oxygen consumption and hemodynamics in patients with chronic severe pulmonary hypertension
M. Lichtblau, J. Weidenhammer, C. Nagel, C. Fischer, M. Halank, H. Klose, M. Hoeper, W. Seeger, H. Olschewski, S. Rosenkranz, H. Wilkens, T. Lange, D. Mertens, M. Held, M. Claussen, C. Opitz, E. Grünig, N. Ehlken (Heidelberg, Dresden, Hamburg, Hannover, Gießen, Cologne, Homburg, Regensburg, Mainz, Würzburg, Großhansdorf, Berlin, Germany; Graz, Austria)
|   |
Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH)
O. Sitbon, R. N. Channick, M. Delcroix, H. A. Ghofrani, P. Jansa, F. O. Le Brun, S. Mehta, L. Perchenet, T. Pulido, L. J. Rubin, B. K. S. Sastry, G. Simonneau, R. Souza, A. Torbicki, N. Galiè (Le Kremlin-Bicêtre, France; Boston, San Diego, United States Of America; Leuven, Belgium; Giessen, Germany; Prague, Czech Republic; Allschwil, Switzerland; London, Canada; Mexico City, Mexico; Hyderabad, India; São Paulo, Brazil; Otwock, Poland; Bologna, Italy)
|  |
Phosphodiesterase inhibitors as promising therapies for cigarette smoke-induced emphysema and pulmonary hypertension (PH) in mice
M. Seimetz, N. Parajuli, A. Pichl, R. T. Schermuly, F. Grimminger, W. Seeger, H. A. Ghofrani, N. Weissmann (Giessen, Germany)
| |
Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA)
E. Mayer, A. Biederman, A. M. D'Armini, E. Grünig, P. Jansa, D. P. Jenkins, N. H. Kim, W. Klepetko, J. Lindner, M. M. Madani, C. Wang, N. Davie, A. Fritsch, H. A. Ghofrani (Bad Nauheim, Heidelberg, Wuppertal, Giessen, Germany; Warsaw, Poland; Pavia, Italy; Prague, Czech Republic; Cambridge, United Kingdom; San Diego, United States Of America; Vienna, Austria; Beijing, China)
| |
The effects of beta-blocker therapy on systolic and diastolic function in pulmonary arterial hypertension: A randomized controlled trial
J. van Campen, C. van der Brugeen, P. Trip, K. de Boer, C. Allaart, L. Handoko, F. de Man, H. J. Bogaard, A. Vonk Noordegraaf (Amsterdam, Netherlands)
| |
Anti-remodeling potencies of the soluble guanylate cyclase activator BAY 41-2272 in human lung fibroblasts
C. Lambers, M. Roth, E. Hofbauer, V. Petkov, L. H. Block (Vienna, Austria; Basel, Switzerland)
| |
Selective inhibition of neutrophil elastase by BAY 85-8501 improves exercise capacity and pulmonary hypertension in a porcine pancreatic elastase-induced emphysema model
M. Delbeck, S. Micus, V. Li, F. Von Nussbaum, D. Meibom, K. Lustig, H. Truebel, S. Schaefer (Wuppertal, Germany)
| |
Oral delivery of transplastomic plant derived angiotensin converting enzyme2 - a novel approach for pulmonary hypertension therapeutics
V. Shenoy, K. C. Kwon, A. Rathinasabapathy, S. Lin, G. Jin, C. Song, P. Shil, A. Nair, Y. Qi, Q. Li, J. Francis, M. Katovich, H. Daniell, M. Raizada (Gainesville, Philadelphia, Baton Rouge, United States Of America)
| |